About
Deck Therapeutics develops THDG3, a semi-synthetic intravenous omega-3 fatty acid glyceride emulsion aimed at neuroprotection for hypoxic-ischemic brain injuries such as neonatal hypoxic-ischemic encephalopathy and ischemic stroke; the compound originated from research at Columbia University.
Explore Deck Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.